Evidence map›Paper›PMID 38026885›Full record

ArticleFrontiers in bioengineering and biotechnology2023

Corrigendum: The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper.

Svetlana V Belenkaya, Iuliia A Merkuleva, Olga I Yarovaya, Varvara Yu Chirkova, Elena A Sharlaeva, Daniil V Shanshin, Ekaterina A Volosnikova, Sergey Z Vatsadze, Mikhail V Khvostov, Nariman F Salakhutdinov and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Svetlana V BelenkayaLaboratory of Bionanotechnology, Microbiology and Virology, Novosibirsk State University, Novosibirsk, Russia.
Iuliia A MerkulevaState Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia.
Olga I YarovayaLaboratory of Bionanotechnology, Microbiology and Virology, Novosibirsk State University, Novosibirsk, Russia.
Varvara Yu ChirkovaDepartment of Physical-Chemistry Biology and Biotechnology, Altay State University, Barnaul, Russia.
Elena A SharlaevaDepartment of Physical-Chemistry Biology and Biotechnology, Altay State University, Barnaul, Russia.
Daniil V ShanshinState Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia.
Ekaterina A VolosnikovaState Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia.
Sergey Z VatsadzeN.D Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Mikhail V KhvostovDepartment of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia.
Nariman F SalakhutdinovDepartment of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia.
Dmitriy ShcherbakovState Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fbioe.2023.1187761.].

Indexed as

3CL proteaseE. coli bacteriaRBDSARS-CoV-2TEV protease

Identifiers

PMID38026885
PMCPMC10658891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.